151 related articles for article (PubMed ID: 30073169)
1. LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion.
Ribeiro MC; Peruchetti DB; Silva LS; Silva-Filho JL; Souza MC; Henriques MDG; Caruso-Neves C; Pinheiro AAS
Front Mol Biosci; 2018; 5():67. PubMed ID: 30073169
[TBL] [Abstract][Full Text] [Related]
2. TSC2/Rheb signaling mediates ERK-dependent regulation of mTORC1 activity in C2C12 myoblasts.
Miyazaki M; Takemasa T
FEBS Open Bio; 2017 Mar; 7(3):424-433. PubMed ID: 28286738
[TBL] [Abstract][Full Text] [Related]
3. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
4. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
5. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway.
Sun JJ; Yin XW; Liu HH; Du WX; Shi LY; Huang YB; Wang F; Liu CF; Cao YJ; Zhang YL
Acta Pharmacol Sin; 2018 Mar; 39(3):336-344. PubMed ID: 29072256
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitor attenuates monocyte adhesion to vascular endothelium through modulation of intracellular zinc.
Kojima C; Kawakami A; Takei T; Nitta K; Yoshida M
J Pharmacol Exp Ther; 2007 Dec; 323(3):855-60. PubMed ID: 17878405
[TBL] [Abstract][Full Text] [Related]
8. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.
Chen XG; Liu F; Song XF; Wang ZH; Dong ZQ; Hu ZQ; Lan RZ; Guan W; Zhou TG; Xu XM; Lei H; Ye ZQ; Peng EJ; Du LH; Zhuang QY
Mol Carcinog; 2010 Jun; 49(6):603-10. PubMed ID: 20512842
[TBL] [Abstract][Full Text] [Related]
10. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
11. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
12. mTORC2 Activation Mediated by Mesenchymal Stem Cell-Secreted Hepatocyte Growth Factors for the Recovery of Lipopolysaccharide-Induced Vascular Endothelial Barrier.
Meng SS; Guo FM; Huang LL; Huang YZ; Xie JF; Yang CS; Qiu HB; Yang Y
Stem Cells Int; 2021; 2021():9981589. PubMed ID: 34707661
[TBL] [Abstract][Full Text] [Related]
13. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin releasing hormone activation of the mTORC2/Rictor complex regulates actin remodeling and ERK activity in LβT2 cells.
Edwards BS; Isom WJ; Navratil AM
Mol Cell Endocrinol; 2017 Jan; 439():346-353. PubMed ID: 27663077
[TBL] [Abstract][Full Text] [Related]
15. Thrombin causes increased monocytic-cell adhesion to endothelial cells through a protein kinase C-dependent pathway.
DiCorleto PE; de la Motte CA
Biochem J; 1989 Nov; 264(1):71-7. PubMed ID: 2513808
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C zeta plays a central role in activation of the p42/44 mitogen-activated protein kinase by endotoxin in alveolar macrophages.
Monick MM; Carter AB; Flaherty DM; Peterson MW; Hunninghake GW
J Immunol; 2000 Oct; 165(8):4632-9. PubMed ID: 11035106
[TBL] [Abstract][Full Text] [Related]
17. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
18. PI3K/mTOR signaling pathways in medulloblastoma.
Mohan AL; Friedman MD; Ormond DR; Tobias M; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2012 Aug; 32(8):3141-6. PubMed ID: 22843885
[TBL] [Abstract][Full Text] [Related]
19. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma.
Liao H; Huang Y; Guo B; Liang B; Liu X; Ou H; Jiang C; Li X; Yang D
Am J Cancer Res; 2015; 5(1):125-39. PubMed ID: 25628925
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
